- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$0.98 BnMarket Estimate, 2026
$1.08 BnMarket Forecast, 2034
$2.32 BnCAGR, 2026–2034
10.04%Executive Summary: Europe Pen Needles Market
- Market Scope: Comprehensive market analysis of the European pen needles industry covering therapies (insulin, GLP-1, and growth hormone therapy), types (standard and safety needles), needle lengths (4mm, 6mm, 8mm, 10mm, 12mm), modes of purchase (retail and non-retail), and country-level landscapes across the UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, the Czech Republic, and the Rest of Europe.
- Market Valuation: Valued at USD 0.98 billion in 2025, estimated at USD 1.08 billion in 2026, and projected to reach USD 2.32 billion by 2034, registering a strong CAGR of 10.04% (2026–2034).
- Primary Growth Drivers: Escalating prevalence of diabetes and obesity rates across European populations; favorable regulatory policies and government safety mandates reducing needlestick injuries; and robust healthcare investments in diabetes research and patient care infrastructure.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment / Position | Growth Dynamics |
|---|---|---|
| By Therapy | Insulin Therapy (commands the largest market share, driven by widespread clinical reliance on insulin pens for diabetes management) | GLP-1 and growth hormone therapies are exhibiting steady growth driven by weight management trends and hormone care needs. |
| By Type | Standard & Safety Needles (standard needles capture high volume due to cost-effectiveness) | Safety pen needles are seeing increasing adoption driven by strict EU health and safety mandates regarding needlestick prevention. |
| By Country | Germany (estimated to account for the largest share of the European market in 2025, supported by excellent healthcare infrastructure and strong reimbursement) | France is estimated to grow at the highest CAGR during the forecast period, backed by comprehensive insurance coverage and an aging demographic. |
Major Market Players & Market Structure
Market Structure: Highly competitive regional marketplace dominated by global medical device leaders partnering with healthcare providers and digital drug delivery platforms.
Key Companies: Becton Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG, UltiMed, Inc., Allison Medical, Inc., Owen Mumford, Ltd., B. Braun Melsungen, Artsana S.p.A., HTL-STREFA S.A., and Terumo Corporation.
Europe Pen Needles Market Size
The Europe pen needles market size was valued at USD 0.98 billion in 2025 and is anticipated to reach USD 1.08 billion in 2026 from USD 2.32 billion by 2034, growing at a CAGR of 10.04% during the forecast period from 2026 to 2034.
Needle manufacturers have produced needles to reduce pain and diminish skin trauma, primarily by innovating needle length and diameter. The primary challenge for needle manufacturers is to keep a sufficient inner lumen while maintaining a sufficiently low injection force. Pen needles are used to administer medication, such as insulin or other injectable medicines, combined with injection pens. A pen needle contains a hollow needle connected to an injection pen. Pen needles are prepared with various needle lengths and used by diabetes patients.
The growing rate of diabetic patients, the existence of favorable regulatory policies to reduce needlestick injuries, the growing focus on the utilization of safety equipment by the government, increasing funds for diabetes care & research in the U.K., and favorable reimbursement policies in Germany are accelerating the growth of the pen needle market in Europe. Additionally, an increasingly aging population & availability of high insurance in France, a growing number of diabetes awareness programs in Italy, and the existence of regulations that mandate the utilization of safety pen needles & the presence of a substantial diabetic population in Spain are further driving the growth of the market in Europe.
The reusability of pen needles, complications associated with needle use, and availability of alternative dosage forms may hamper the region's market growth. Lack of knowledge among people on pen needle utilization and uncertain reimbursement policies across Europe are restraining the development of the pen needle market in Europe.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| CAGR | 10.04% |
| Segments Covered | By Therapy, Type, Needle Length, Mode Of Purchase and Region |
| Various Analyses Covered | Global, Regional and Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Regions Covered | UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, the Netherlands, Turkey, the Czech Republic, and the Rest of Europe. |
| Market Leaders Profiled | Becton Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG, UltiMed, Inc., Allison Medical, Inc., Owen Mumford, Ltd., B. Braun Melsungen, Artsana S.p.a., HTL-STREFA S.A., and Terumo Corporation. |
REGIONAL ANALYSIS
In this region, Germany is estimated to account for the largest share of the Europe pen needles market in 2025. In contrast, France is estimated to grow at the highest CAGR during the forecast period. Europe is expected to see an overall boost in the pen needle market due to the rising prevalence of its target disease. Moreover, the U.K. government is also taking initiatives to invest in diabetes care and research to improve diabetic patients' treatment techniques. Europe is projected to dominate the global market due to a rise in the prevalence of diabetes among all ages, technological advancements, and an increase in research and development activities on diabetes care. This dominance may also be due to a rise in overweight & obesity, unhealthy diet, and physical inactivity.
KEY MARKET PLAYERS
Companies that play a promising role in the Europe pen needles market include
- Becton Dickinson and Company
- Novo Nordisk A/S
- Ypsomed Holding AG
- UltiMed, Inc.
- Allison Medical, Inc.
- Owen Mumford, Ltd.
- B. Braun Melsungen
- Artsana S.p.A.
- HTL-STREFA S.A.
- Terumo Corporation
RECENT MARKET HAPPENINGS
- In February 2019, Bigfoot Biomedical, Inc. and Owen Mumford Ltd. announced a supply to assist with the pen needles in Bigfoot's subscription supply bundles. This contract will confirm that the customers continuously have access to a contented and high-quality pen needle for every insulin dose. It would also help evolve a digital drug delivery platform projected for sustained insulin delivery to all people with insulin-requiring diabetes.
- In 2018, Becton, Dickinson, and Company (U.S.) launched its BD Ultra-Fine micro pen needle 6mm x 32G.
MARKET SEGMENTATION
This research report on the European pen needles market has been segmented and sub-segmented based on therapy, type, needle length, mode of purchase, and country.
By Therapy
- Insulin Therapy
- GLP-1 Therapy
- Growth Hormone Therapy
By Type
- Standard Needle
- Safety Needle
By Needle Length
- 4mm
- 6mm
- 8mm
- 10mm
- 12mm
By Mode of Purchase
- Retail
- Non-Retail
By Country
- The UK
- France
- Spain
- Germany
- Italy
- Russia
- Sweden
- Denmark
- Switzerland
- Netherlands
- Turkey
- Czech Republic
- Rest of Europe